Pediatrix Medical Group (FRA:PDC) Research & Development: €0 Mil (TTM As of Mar. 2026)


FRA:PDC Pediatrix Medical Group Inc FRA:PDC
63 GF Score
Price €20.40
GF Value €11.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Pediatrix Medical Group Research & Development?

Pediatrix Medical Group FRA:PDC -0.97% 63 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates FRA:PDC with a GF Score™ of 63/100 and a GF Value™ of €11.23 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pediatrix Medical Group's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Pediatrix Medical Group  (FRA:PDC) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pediatrix Medical Group Research & Development Related Terms

Pediatrix Medical Group Research & Development Historical Data

* Premium members only.

The historical data trend for Pediatrix Medical Group's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pediatrix Medical Group Research & Development Chart

Pediatrix Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Pediatrix Medical Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:PDC
63GF Score
Pediatrix Medical Group Inc FRA:PDC
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pediatrix Medical Group Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Pediatrix Medical Group (FRA:PDC) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Pediatrix Medical Group and its competitors.
Is Pediatrix Medical Group's Research & Development too high?
Pediatrix Medical Group's current Research & Development is €0 Mil. Overall, Pediatrix Medical Group has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Research & Development compare to SGRY and ADUS?
Pediatrix Medical Group's Research & Development of €0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pediatrix Medical Group and its competitors. Pediatrix Medical Group's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.23, compared to a current price of €20.40 — trading 81.7% above its estimated fair value. The current Research & Development is €0 Mil. Pediatrix Medical Group's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?

Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued. The current stock price of €20.40 is trading 81.7% above its estimated GF Value™ of €11.23. GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.

Key valuation signals for FRA:PDC:

  • Research & Development: €0 Mil
  • GF Value™: €11.23 vs. price of €20.40 (81.7% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pediatrix Medical Group Business Description

Other Exchanges MD:USA
Address 1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
63GF Score

Get the complete analysis for FRA:PDC

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.40
Price
€11.23
GF Value